- Price
- $9.47
- Day
- +3.05%
- Mkt Cap
- $840.69M
- 52W Range
- $5.45 – $12.49
- Volume
- 1.01M
- Beta
- 0.38
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma Transcript
Read full article
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –
Read full article
Kura Oncology NASDAQ: KURA presented updated results from its Phase 1 FIT-001 trial evaluating darlifarnib in combination with cabozantinib for locally advanced or metastatic renal cell carcinoma (RCC) that had progressed after prior treatment, including immunotherapy.
Read full article